RT Journal Article
SR Electronic
T1 Deep profiling of multiple ischemic lesions in a large, multi-center cohort: Frequency, spatial distribution, and associations to clinical characteristics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.01.22277062
DO 10.1101/2022.07.01.22277062
A1 Bonkhoff, Anna K.
A1 Ullberg, Teresa
A1 Bretzner, Martin
A1 Hong, Sungmin
A1 Schirmer, Markus D.
A1 Regenhardt, Robert W.
A1 Donahue, Kathleen L.
A1 Nardin, Marco J.
A1 Dalca, Adrian V.
A1 Giese, Anne-Katrin
A1 Etherton, Mark R.
A1 Hancock, Brandon L.
A1 Mocking, Steven J. T.
A1 McIntosh, Elissa C.
A1 Attia, John
A1 Cole, John W.
A1 Donatti, Amanda
A1 Griessenauer, Christoph J.
A1 Heitsch, Laura
A1 Holmegaard, Lukas
A1 Jood, Katarina
A1 Jimenez-Conde, Jordi
A1 Kittner, Steven J.
A1 Lemmens, Robin
A1 Levi, Christopher R.
A1 McDonough, Caitrin W.
A1 Meschia, James F.
A1 Phuah, Chia-Ling
A1 Ropele, Stefan
A1 Rosand, Jonathan
A1 Roquer, Jaume
A1 Rundek, Tatjana
A1 Sacco, Ralph L.
A1 Schmidt, Reinhold
A1 Sharma, Pankaj
A1 Slowik, Agnieszka
A1 Sousa, Alessandro
A1 Stanne, Tara M.
A1 Strbian, Daniel
A1 Tatlisumak, Turgut
A1 Thijs, Vincent
A1 Vagal, Achala
A1 Woo, Daniel
A1 Zand, Ramin
A1 McArdle, Patrick F.
A1 Worrall, Bradford B.
A1 Jern, Christina
A1 Lindgren, Arne G.
A1 Maguire, Jane
A1 Wu, Ona
A1 Frid, Petrea
A1 Rost, Natalia S.
A1 Wasselius, Johan
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/07/05/2022.07.01.22277062.abstract
AB Background A substantial number of patients with acute ischemic stroke (AIS) experience multiple acute lesions (MAL). However, the spatial distribution and clinical implications of such MAL are incompletely understood.Methods Analyses relied upon imaging and clinical data of patients with AIS from the international MRI-GENIE study. Initially, we systematically evaluated the occurrences of MAL within (i) one and, (ii) several vascular supply territories. Associations between the presence of MAL and important characteristics, such as DWI lesion volume, NIHSS-based acute stroke severity, and long-term functional outcome were subsequently determined. The interaction effect between single and multiple lesion status and DWI lesion volume was estimated by means of Bayesian regression modeling for stroke severity and functional outcome.Results We analyzed 2,466 patients [age: 63.4±14.8, 39% women], 49.7% of which presented with single lesions. Another 37.4% experienced MAL in a single vascular territory, while 12.9% featured lesions in several territories. Within most territories (anterior, middle, and posterior cerebral artery, cerebellar), multiple lesions occurred as frequently as single lesions (ratio ∼1:1). Only the brainstem region comprised fewer patients with multiple lesions (ratio ∼1:4). Patients with MAL presented with a significantly higher DWI lesion volume and acute NIHSS (7.7ml vs. 1.7ml and 4 vs. 3, pFDR≤0.001). In contrast, patients with a single lesion were characterized by a significantly higher WMH burden (6.1ml versus 5.3ml, pFDR=0.048). Functional outcome did not differ significantly between patients with single versus multiple lesions. Bayesian analyses suggested that the association between DWI lesion volume and stroke severity between single and multiple lesions was the same in case of anterior circulation stroke. In the case of posterior circulation stroke, DWI lesion volume was linked to a higher acute NIHSS only among those with multiple lesions.Conclusions Multiple lesions, especially those within one vascular territory, occurred more frequently than previously reported. Overall, multiple lesions were distinctly linked to a higher acute stroke severity, a higher DWI lesion volume and lower WMH lesion volume. In posterior circulation stroke, lesion volume was linked to a higher stroke severity in multiple lesions only.Competing Interest StatementM.E. has received personal fees for consulting from Astra Zeneca and WorldCare Clinical Group. C.G. has received consulting honoraria from Microvention and Strykere and research funding from Medtronic and Penumbra. A.V. has received research funding from Cerenovus. A.G.L. has received personal fees from Bayer, Astra Zeneca, BMS Pfizer, and Portola. N.S.R. has received compensation as scientific advisory consultant from Omniox, Sanofi Genzyme and AbbVie Inc. T.U. received personal fees for consulting from AstraZeneca. All other authors declare no competing interests.Funding StatementA.K.B. is supported by a Massachusetts General Hospital Executive Committee on Research (MGH ECOR) Fund for Medical Discovery (FMD) Clinical Research Fellowship Award. M.B. acknowledges support from the Societe Francaise de Neuroradiologie, Societe Francaise de Radiologie, Fondation ISITE-ULNE. A.V. is in part supported by National Institutes of Health and National Institute of Neurological Disorders and Stroke (NIH-NINDS, R01 NS103824, RF1 NS117643, R01 NS100417, U01NS100699, U01NS110772). C.J. acknowledges support from the Swedish Research Council (2018-02543 and 2021-01114), the Swedish state under the agreement between the Swedish government and the county councils, the "Avtal om Lakarutbildning och Medicinsk Forskning" (ALF) agreement (ALFGBG-720081); the Swedish Heart and Lung Foundation (20190203). A.G.L. acknowledges support from the Swedish Research Council (2019-01757), The Swedish Government (under the "Avtal om Lakarutbildning och Medicinsk Forskning, ALF"), The Swedish Heart and Lung Foundation, Region Skane, Lund University, Skane University Hospital, Sparbanksstiftelsen Fars och Frosta, Fremasons Lodge of Instruction Eos in Lund and National Institutes of Health (NIH, 1R01NS114045-01). N.S.R. is in part supported by National Institutes of Health and National Institute of Neurological Disorders and Stroke (NIH-NINDS, R01NS082285, R01NS086905, U19NS115388).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients gave written informed consent in accordance with the Declaration of Helsinki. The study protocol was approved by Massachusetts General Hospital's Institutional Review Board (Protocol #: 2001P001186 and 2003P000836).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available to researchers for the purpose of reproducing the here reported results, pending the permission for data sharing by Massachusetts General Hospital's institutional review board.